Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.A5 Laboratories has acquired Contract Research (CRO) and Interferon production technology assets. A5 Labs is now planning to secure the intellectual property related to the interferon production technology as well as complete its plans for pilot scale production and commercialisation of interferon products for veterinary and human applications.
Subscribe to our email newsletter
With acquisition, A5 Labs has established the capacity for contract analytical, product development, regulatory and testing services in the pharmaceutical and environmental sector.
Richard Azani, president and CEO of A5 Labs, said: “We are very pleased to complete the acquisition of the CRO and Interferon production technology assets. We now have at our disposal the necessary assets to develop and commercialise novel biotechnology products.”
A5 Labs is a contract research based organisation servicing the pharmaceutical and biotechnology companies in North America. The company utilises its research capabilities to license and acquire novel biotechnology products for development and commercialisation.